FSD Pharma Inc. ( HUGE) Stock. Should you Buy or Sell? $ 0.92
-0.01 (-0.40 %)
FSD Pharma Inc. Analysis
Updated on 10-09-2022| Symbol | HUGE |
| Price | $0.92 |
| Beta | 0.947 |
| Volume Avg. | $60 thousand |
| Market Cap | $35.06 M |
| 52 Week Range | $0.695 - $1.78 |
FSD Pharma Inc. opened the day at $0.92 which is -0.40 % on yesterday's close. FSD Pharma Inc. has a 52 week high of $1.78 and 52 week low of $0.695, which is a difference of $1.085. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $35.06 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy FSD Pharma Inc. for $35.06 M, it would take 15 years to get your money back. FSD Pharma Inc. are in the Drug Manufacturers—Specialty & Generic space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
FSD Pharma Inc. Stock Forecast - Is FSD Pharma Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -1.571 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing FSD Pharma Inc.
| Price Book Value Ratio | 0.829 | Price To Book Ratio | 0.829 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -1.571 |
How liquid is FSD Pharma Inc.
| Current Ratio | 3.982 |
| Quick Ratio | 3.813 |
Debt
| Debt Ratio | 0.168 | Debt Equity Ratio | 0.202 |
| Long Term Debt To Capitalization | 0.001 | Total Debt To Capitalization | 0.012 |
Latest news about FSD Pharma Inc.
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201. The Toronto-based biopharma firm said the corresponding study protocol is titled "A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma (CSE:HUGE, NASDAQ:HUGE).
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration (FDA) and Health Canada for its planned Phase 2 clinical trial of FSD-201 for the treatment of a yet-to-be-disclosed inflammatory disorder. The biotech noted that FSD-201, its proprietary formulation of ultra micronized palmitoylethanolamide, or ultramicronized PEA, was shown to be safe and well tolerated during a Phase 1 clinical trial.
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that it has closed the sale of its former cannabis processing facility in Cobourg, Ontario, Canada for gross proceeds of $16.4 million in cash. The facility became non-essential to FSD Pharma after it decided in early 2020 to exit the cannabis production market to focus on the biotech market, advancing novel drug candidates targeting lucrative areas of unmet medical needs like Muscular Sclerosis, Depression Disorders, and Inflammatory Disorders.
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc. announced that it is expanding its management and advisory teams.
About FSD Pharma Inc.
Description :
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
